

- a. Identifying and evaluating biomarkers and incorporating such biomarkers into clinical risk assessment scoring algorithms for use in high- (patient) and low- (unprovoked) risk populations.
- b. Evaluate the effectiveness of existing antithrombotic agents in preventing VTE in high-risk populations.
- c. Identifying new therapeutic targets for the development of effective antithrombotics with the ultimate goal of discovering agents that do not cause bleeding.